Volume 26, Issue 10 (12-2019)
RJMS 2019, 26(10): 87-94 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nikfarjam A, pornour M, Sohrabi M. The expression of Hsa-miR-490 in peripheral blood circulation of patients with breast cancer. RJMS 2019; 26 (10) :87-94
URL: http://rjms.iums.ac.ir/article-1-5879-en.html
URL: http://rjms.iums.ac.ir/article-1-5879-en.html
ACECR , Pornour@acecr.ac.ir
Abstract: (2692 Views)
Background: Cancer is the second most common cause of death after cardiovascular disease in worldwide and developed countries. Breast cancer is one of the major causes of mortality in women. Mortality from breast cancer is significantly reduced with early detection. There are several detection methods. One way is investigate the changes of microRNA expression in serum / plasma. In this study, we examined the expression of hsa-miR-490 in serum that obtained from patients with breast cancer.
Methods: In a cross-sectional comparative study, peripheral blood samples were collected from 30 subjects with breast cancer and 30 healthy individuals as a control group. Total mRNA was extracted from serum and cDNA was synthesized to study the hsa-miR-490-5p gene expression variations by real-time PCR.
Results: Significant increase was observed in gene expression and sera concentration of hsa-miR-490-5p in serum of breast cancer patient. Significant changes were not observed in gene expression of hsa-miR-490-3p in serum of breast cancer patient.
Conclusion: The obtained results indicated that hsa-miR-490-5p acts as oncomir in serum by targeting FOXP3 (p<0.05).
Methods: In a cross-sectional comparative study, peripheral blood samples were collected from 30 subjects with breast cancer and 30 healthy individuals as a control group. Total mRNA was extracted from serum and cDNA was synthesized to study the hsa-miR-490-5p gene expression variations by real-time PCR.
Results: Significant increase was observed in gene expression and sera concentration of hsa-miR-490-5p in serum of breast cancer patient. Significant changes were not observed in gene expression of hsa-miR-490-3p in serum of breast cancer patient.
Conclusion: The obtained results indicated that hsa-miR-490-5p acts as oncomir in serum by targeting FOXP3 (p<0.05).
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
